When Cost-Cutting in the Clinical Pathology Laboratory Collides with Effective QA/QC: How Savvy Labs Sustain the Accuracy and Quality of their Lab Test Results

Sep 4, 2013 | Coding, Billing, and Collections, Digital Pathology, Laboratory Hiring & Human Resources, Laboratory Management and Operations, Laboratory News, Laboratory Operations, Laboratory Pathology, Management & Operations, News From Dark Daily

As medical laboratories struggle to reduce costs and squeeze their budgets, it is essential that the lab’s quality assurance/quality control program is run properly to protect and enhance the analytical integrity of lab test results When does budget cutting in a clinical laboratory begin to undermine the accuracy and analytical integrity of the medical laboratory test results produced by the laboratory? This question is apparently a subject of much discussion within some lab organizations...

It’s Back on the Table! Medicare Patient Co-Pay for Clinical Laboratory Tests Is One of 27 Cost-Cutting Proposals in Federal Debt Ceiling Negotiations

Jul 15, 2011 | Laboratory News, Laboratory Pathology, Managed Care Contracts & Payer Reimbursement

Document leak earlier this week pulls curtain back on potential cuts to Medicare/Medicaid spending Spending cuts of between $334 billion and $353 billion over the next 10 years are on the table in the negotiations over the federal debt ceiling. The bad news for the clinical laboratory industry is that restoration of the Medicare patient co-pay for medical laboratory tests is not only on the list of proposed spending cuts, but represents a significant chunk of money—as much as $16 billion...

Cuts in Health Budgets Are Threat and Opportunity for Clinical Pathology Laboratories

Mar 22, 2010 | Laboratory News, Laboratory Pathology, News From Dark Daily

Some clinical labs use new pathology lab test technologies to deliver added value to physicians, patients, and payers Clinical pathology laboratories in the United States and other developed countries across the globe face an unprecedented double-whammy. On one hand, the ongoing explosion of genetic and molecular knowledge gives pathologists and clinical laboratories incredible new tools for diagnosing disease and guiding therapy. On the other hand, funding for government health programs in...
;